Target: Carbonic Anhydrase IX.
Specificity: Detects human Carbonic Anhydrase IX. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Girentuximab Biosimilar - Research Grade.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: RUO girentuximab binds to the extracellular proteoglycan (PG)-like domain, which is unique to CA IX compared to other isoforms and lies adjacent to the catalytic domain. In addition to therapy, girentuximab has also been utilized as an imaging agent.
Concentration: 5mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
